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Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly 
being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either 
intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been 
proposed among the strategies to improve engraftment. In the current study, we have assessed the effects of both 
approaches. Thus, NOD/SCID recipients were transplanted with human UCB CD34+ cells administered either 
intravenously (IV) or IB, receiving or not bone marrow (BM)-derived MSCs also IV or IB (in the right femur). 
Human HSC engraftment was measured 3 and 6 weeks after transplantation. Injected MSCs were tracked weekly 
by bioluminescence. Also, lodgment within the BM niche was assessed at the latter time point by immuno-
fluorescence. Our study shows regarding HSC engraftment that the number of BM human CD45+ cells detected 
3 weeks after transplantation was significantly higher in mice cotransplanted with human MSCs. Moreover, these 
mice had a higher myeloid (CD13+) engraftment and a faster B-cell (CD19+) chimerism. At the late time point 
evaluated (6 weeks), human engraftment was higher in the group in which both strategies were employed (IB 
injection of HSC and MSC coadministration). When assessing human MSC administration route, we were able 
to track MSCs only in the injected femurs, whereas they lost their signal in the contralateral bones. These human 
MSCs were mainly located around blood vessels in the subendosteal region. In summary, our study shows that 
MSC coadministration can enhance HSC engraftment in our xenogenic transplantation model, as well as IB 
administration of the CD34+ cells does. The combination of both strategies seems to be synergistic. Interestingly, 
MSCs were detected only where they were IB injected contributing to the vascular niche.
Key words: Mesenchymal stem cells (MSCs); Cordon blood transplantation;  
Bone marrow microenvironment; Hematopoietic engraftment
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) using 
umbilical cord blood (UCB) is increasingly being used 
in order to treat malignant or nonmalignant hematologic 
diseases (24,31,32,41). UCB-HSCT is a suitable proce-
dure in pediatric patients, but in adults, the hematopoi-
etic recovery is slower than with bone marrow (BM) or 
peripheral blood (PB) transplantation (56). In a number 
of cases, engraftment is impaired or even absent, mainly 
because of the lower cellular dose, but other factors such 
as impaired microenvironment after intensive doses of 
chemoradiotherapy may also contribute to this (16,42). 
In order to increase hematopoietic recovery in the UCB 
transplantation setting, several approaches have been 
designed (16,42). Ex vivo expansion of hematopoietic stem 
cells (HSCs) has been proposed as a feasible method, but 
graft improvement has been hampered by HSC exhaus-
tion in most experimental conditions (18,50). The use 
of a double cord blood unit transplantation (DCBT) has 
shown faster engraftment when compared to single-unit 
transplant, but limitations remain for a number of reasons 
(25,45). A third approach has been the infusion of third-
party donor-mobilized HSCs, T-cells depleted, along with 
UCB transplantation as a “bridge engraftment” strategy 
till the engraftment of the latter, but their results are still 
very preliminary (10). 
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Two additional methods have been recently proposed: 
direct intrabone (IB) transplantation of UCB cells (22) or 
the coadministration of mesenchymal stem cells (MSCs) 
along with HSCs (30,37). The faster hematopoietic recov-
ery with the first proposed method could be due to a bet-
ter stem cell homing, preventing the cell loss observed 
when cells are infused intravenously (IV) (3).
The second approach is based on the fact that BM 
MSCs contribute to most cell types involved in BM HSC 
niches (36). They regulate BM homeostasis by cell-to-
cell contact and through cytokine production (36). Also, 
these cells have shown immunomodulatory and anti-
 inflammatory properties (33,47). These properties make 
them an attractive therapeutic tool in UCB transplanta-
tion setting to enhance engraftment. Although several 
studies have been designed to investigate MSC capability 
to enhance hematopoietic engraftment as well as the mecha-
nisms involved, controversial information has been pub-
lished about their migration, engraftment capacity, and 
function after in vivo injection (17,37).
In this study, we have compared both procedures, IB 
administration of UCB cells and MSC injection in an ani-
mal model, in order to ascertain whether one of them or 
both could ameliorate hematopoietic engraftment.
MATERIALS AND METHODS
MSC Isolation, Expansion, and Characterization
Human MSCs were isolated from BM cells of 20 healthy 
volunteer donors (11 males/9 females) with a median age 
of 43 years (range, 25–49 years) after informed consent had 
been obtained, in accordance with the local ethics commit-
tee of the University Hospital of Salamanca. Ten to 20 ml 
of BM were taken by iliac crest aspiration under local 
anesthesia according to standard institutional procedures. 
Mononuclear cells (MNCs) were isolated by Ficoll-Paque 
density gradient centrifugation (GE Healthcare Bio-
Sciences, Uppsala, Sweden) and resuspended in Dulbecco’s 
modified Eagle’s medium–low glucose (DMEM) (Gibco, 
Invitrogen, Paisley, UK) supplemented with 10% fetal calf 
serum (FCS) (BioWhittaker, Lonza, Verviers, Belgium) 
and 1% penicillin/streptomycin (Gibco), as previously 
reported (5,46). Cells were seeded at an initial density 
of 106 cells/cm2 and incubated in a humidified atmo-
sphere with 5% CO2. MSCs were expanded in T75 cul-
ture flasks (Corning, Corning, NY, USA) and expanded as 
previously described. After the third passage, MSCs were 
assessed following the minimal criteria recommended 
by the International Society for Cellular Therapy (ISCT) 
(9). Differentiation capacity to osteoblast, adipocytes, and 
chondrocytes was done using NH Osteodiff Medium, NH 
Adipodiff Medium, and NH Chondrodiff Medium, respec-
tively (Miltenyi Biotec, Bergisch Gladbach, Germany), as 
previously described (5). For immunophenotypic analysis, 
MSCs were incubated for 15 min with fluorescein isothio-
cyanate (FITC)-conjugated cluster of differentiation 90 
(CD90), FITC-conjugated CD44, FITC-conjugated CD34, 
phycoerythrin (PE)-conjugated CD73, PE-conjugated 
CD14, PE-conjugated CD166, phycoerythrin-cyanine 5 
(PC5)-conjugated anti-human leukocyte antigen (HLA)- 
DR, PC5-conjugated CD45, and PC5-conjugated CD19 
(all from Becton Dickinson Biosciences, San Jose, CA, USA) 
and allophycocyanine (APC)-conjugated CD105 (R&D 
Systems, Minneapolis, MN, USA). Measurements were 
made on a FACSCalibur flow cytometer (Becton Dickinson 
Biosciences). Data were analyzed using the Infinicyt 
program (Cytognos, Salamanca, Spain), as previously 
described (8).
CD34+ Cell Selection
A total of 20 fresh human UCB units (from 9 male and 
11 female subjects) were obtained from the Barcelona 
Blood and Tissue Bank according to their ethical rules. 
Eighty to 100 ml of heparinized cord blood was diluted in 
phosphate-buffered saline (PBS; Gibco). MNCs were iso-
lated by Ficoll-Paque density gradient centrifugation, and 
then CD34+ progenitor cells were isolated by magnetic 
labeling using the human CD34 MicroBead Kit (Milteny 
Biotec) in accordance with the manufacturer’s protocol. 
After isolation, the purity of CD34+ cells was evaluated 
by flow cytometry using FITC-conjugated CD34 (Becton 
Dickinson Biosciences).
Lentiviral Vector
For the lentiviral vector (LV) used in this study, a 1.7-kb 
Luc2 fragment was isolated from pGL4.10(luc2) vector 
(Promega, Madison, WI, USA) using XhoI and XbaI restric-
tion sites. Subsequently, this Luc2 fragment was cloned 
in the LV pRRL central polypurine tract cytomegalovi-
rus internal ribosome entry site green fluorescent protein 
woodchuck hepatitis virus posttranscriptional regu latory 
element self-inactivating vector [pRRL-cPPT-CMV-IRES-
GFPPRE-SIN, kindly provided by Prof. Hoeben, Leiden 
University Medical Center, Leiden, The Netherlands 
(4)] using the same restriction sites, downstream of the 
CMV promoter, to generate pRRL-cPPT-CMV-Luc2-
IRESGFP-PRE-SIN. Expression of the luciferase gene 
driven by the CMV promoter was confirmed with in vitro 
assays (11,12).
Transfection of Virus-Producing Cells
For virus production, 2 ´  106 human embryonic kidney 
(HEK) 293T cells (kindly provided by Prof. J. P. Bolaños, 
from the University of Salamanca, Spain) were seeded on a 
15-cm diameter culture dishes (BD Falcon, San Jose, CA, 
USA) 1 day before transfection and maintained in DMEM 
supplemented with 10% FCS and the antibiotics penicil-
lin (100 U/ml) and streptomycin (0.1 mg/ml). Briefly, 
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293T cells were transfected with the envelope vector pLV-
vesicular stomatitis Indiana virus G protein (VSVG), the 
packaging vector psPax2, and the LV vector containing 
the luciferase (Luc2) gene pRRL-cPPT-CMV-IRES-GFP-
PRE-SIN by using the calcium phosphate DNA precipi-
tation method, as previously described (15). The medium 
containing lentiviral supernatant was collected at 48 h after 
transfection, filtered through a 0.45-mm pore filter (BD 
Falcon), pooled, and stored at −80°C until use. The titer of 
the virus supernatant was estimated by transducing 293T 
cells with different dilutions, and the transduction effi-
ciency was determined by flow cytometry analysis of GFP. 
Titer was calculated using the following formula: (cell 
concentration at the day of transduction) ´  (virus superna-
tant dilution) ´  (% GFP-positive cells)/total volume.
MSC Transduction
Passage 2 MSCs were transduced when a 50% conflu-
ence of the stromal layer was observed. Transductions were 
carried out in the presence of 8 mg/ml of hexadimethrine 
bromide (polybrene; Sigma-Aldrich, Steinheim, Germany) 
and 1:8 LV supernatants, resulting in a multiplicity of infec-
tion of 1.5. After 24 h, the transduction medium was replaced 
with a fresh medium. At 90% confluence, cells were har-
vested, and GFP+ cells were analyzed by flow cytometry to 
determine transduction efficiency. The multiplicity of infec-
tion (MOI) used in this experiment was 1.5, resulting in a 
transduction efficiency of the MSCs of >70% on the basis of 
GFP expression analyzed by flow cytometry.
Transplantation of NOD/SCID Mice
Six-week-old nonobese diabetic severe combined immu-
nodeficient (NOD/SCID; NOD.CB17-Prkdcscid/NcrCrl) 
mice were purchased from Charles River Laboratories 
(Barcelona, Spain), housed in microisolator cages, and 
maintained under sterile conditions in the animal facility 
of the University of Salamanca. All procedures followed 
the Spanish and European Union guidelines (RD 1201/05 
and 86/609/CEE, respectively) and were approved by the 
Bioethics Committee of the University of Salamanca (reg. 
no. 201100007924). The NOD/SCID mouse transplant 
model was established as reported previously with modifi-
cations (20). A total of 100 female mice were used for these 
experiments (20 per experimental group). Six to 8 h before 
transplantation, animals were exposed to 300 cGy total 
body irradiation from a cesium (CS) source (Gammacell-
200, Nordion International, Ottawa, ON, Canada). In this 
study, the IV or intrabone (IB) injection as well as the coad-
ministration of MSCs were combined to test their effect 
on hematopoietic engraftment according to the following 
transplantation groups: (1) 105 IV CD34+ cells; (2) 105 IV 
CD34+ cells and 5 ´  105 IB MSCs; (3) 105 IV CD34+ cells 
and 5 ´  105 IV MSCs; (4) 105 IB CD34+ cells; (5) 105 IB 
CD34+ cells and 5 ´  105 IB MSCs. Before transplantation, 
animals were anesthetized with a mixture of ketamine 
(90 mg/kg; Imalgene 500, Merial, Lyon, France) and 
xylazine (10 mg/kg; Rompun 2%, KVP Pharma, Bayer 
Healthcare, Kiel, Germany). For IV injection, cells were 
resuspended in a total volume of 200 ml of PBS and slowly 
injected by tail vein. For IB injection, cells were injected 
through the knee into the femur in a total volume of 20 ml 
of PBS. Animals were transplanted with MSCs from an 
adult donor and HSCs from a pool of three to four different 
UCB units, being all units from same sex donor for each 
pool. There were sex mismatches between HSC and MSC 
donors. Hematopoietic engraftment was evaluated by flow 
cytometry at weeks 3 and 6 after transplantation in periph-
eral blood (PB), injected femur (right femur), and contral-
ateral femur (left femur) samples (52). Six weeks after 
transplantation, mice were killed, and their femurs were 
fixed in 4% formaldehyde (Panreac, Barcelona, Spain) for 
immunohistological analysis.
Analysis of Human Hematopoietic Engraftment  
by Flow Cytometry
For flow cytometry studies, PB was obtained from mice 
eye vein and BM samples from both femurs. All cell sus-
pensions were collected in PBS, subjected to red cell lysis 
by treatment with ammonium chloride, washed once, and 
then resuspended again in PBS. To analyze human hema-
topoietic cells engraftment, samples were stained with 
FITC-conjugated anti-human CD45 (Miltenyi Biotec). 
For multilineage detection, cells were stained with APC-
conjugated CD3, PE-conjugated CD13, PE-conjugated 
CD14, and APC-conjugated CD19 (all from Becton 
Dickinson Biosciences). In all cases, 10 min before acqui-
sition, samples were stained with 7-amino-actinomycin D 
(7-AAD; Becton Dickinson Biosciences). An unstained 
control was also included for each sample. For data analy-
sis, hematopoietic cells were gated by forward/side scatter 
to exclude potential contamination with GFP-transduced 
MSCs. Then, CD45 expression was used to gate human 
cells and 7AAD to exclude dead cells. Finally, human 
hematopoietic subpopulations were detected by CD3 
(T-cells), CD13 (myeloid cells), CD14 (monocytes), and 
CD19 (B-cells) expression within the human CD45+ live 
gate. In addition, as previously indicated, a control unstained 
sample was acquired in each study of PB or BM, and rare 
unspecific positive event (if any) values were subtracted to 
the values of the positive events for each marker.
In Vivo Bioluminescence
In order to track the mesenchymal population in vivo, 
bioluminescence images (BLI) were acquired weekly using 
a Xenogen IVIS 50 (Caliper Life Sciences, Alameda, CA, 
USA) bioluminescence/fluorescence optical imaging sys-
tem at different time points. A few minutes before BLI, the 
mice were anesthetized with isoflurane (1–3%) (Forane, 
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Abbot Laboratories, Madrid, Spain). Mice were given the 
substrate d-luciferin (150 mg/kg in PBS) (Promega) by 
intraperitoneal injection. Ten minutes after administration 
of substrate, the anesthetized mice were placed onto the 
warmed stage inside the light tight camera box with contin-
uous exposure to isoflurane (1–2%). After acquiring photo-
graphic images of mice, luminescent images were acquired 
with 2-min exposure times. Exposure conditions (time, 
aperture, stage position, binning, and time after injection) 
were kept identical in all measurements. For quantification, 
standard regions of interest (ROIs) were defined for femurs 
and lungs separately. Measurements were expressed as pho-
tons per second. The resulting gray scale photographic and 
pseudocolor luminescent images were automatically super-
imposed so that identification of any optical signal with 
location on the mouse was facilitated. Optical images were 
displayed and analyzed with IVIS Living Image (Caliper 
Life Sciences) software packages.
Immunohistochemistry
Femurs were fixed, decalcified for 24 h, and embedded 
in paraffin, and 5-µm-thick tissue sections were placed on 
glass slides. The sections were then incubated with 5% 
normal donkey serum and bovine serum albumin to block 
nonspecific binding. In order to detect cells from human 
origin, a primary antibody for human mitochondria 
detection (Millipore, Billerica, MA, USA) was used. For 
detection of human MSCs, endogenous GFP signals were 
amplified by staining sections with rabbit anti-GFP anti-
body (AbCam, Cambridge, UK). As secondary antibody, 
Alexa Fluor448-conjugated anti-rabbit IgG and Alexa555 
anti-mouse IgG were used (both from Invitrogen). After 
washes, 1 µg/ml 4¢,6-diamidine-2¢-phenyl indole, dihy-
drochloride (DAPI; Sigma-Aldrich) in PBS was added, 
and the cells were incubated at room temperature for 
5 min. Slides were viewed with a Leica DMI6000B 
fluo rescence microscope (Leica Microsystems GmbH, 
Wetzlar, Germany) equipped with camera system.
Statistical Analysis
Median and ranges were calculated for each variable. 
To estimate the significance of the differences between the 
groups, the nonparametric Mann–Whitney U test was used. 
As a result of multiple subgroup assessments, a modified 
Figure 1. Human hematopoietic engraftment in nonobese diabetic/severe combined immunodeficient (NOD/SCID) bone marrow. 
Percentage of human CD45+ cells in bone marrow samples from both femurs, right (A, C) (injected site) and left (contralateral) (B, D), 
at 3 (A, B) and 6 (C, D) weeks after transplantation. Results expressed as medians (range). IV, intravenous injection; IB, intrabone 
injection in right femur; CD34, human CD34+ cells; MSC, mesenchymal stem cells.
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Bonferroni correction (a/5) was used to adjust the p value. 
Differences were considered to be significant for values of 
p < 0.05. All statistical analyses were done with SPSS 17.0 
(Chicago, IL, USA).
RESULTS
MSCs from BM samples were expanded in all cases. 
All of them adhered to plastic surfaces; were capable of 
differentiating into adipocytes, osteoblasts, and chondro-
cytes; expressed the antigens CD44, CD73, CD90, CD105, 
and CD166; and were negative for hematopoietic antigens 
following the criteria defined by the ISCT (9) for MSC use. 
In all cases, we were able to transduce MSCs. Transduction 
efficiency of the MSCs was >70% on the basis of GFP 
expression analyzed by flow cytometry (data not shown).
CD34+ cells were isolated from all UCB samples. Cell 
purity was above 85% in all cases.
Human Hematopoietic Engraftment
In order to test the optimal transplantation combina-
tion, human hematopoietic engraftment was analyzed in 
NOD/SCID mice. Human cells were detected in all cases 
Figure 2. Human hematopoietic cells in NOD/SCID peripheral blood. Percentage of human CD45+ in total mononuclear cells in 
peripheral blood (A, B) as well as percentage of myeloid CD13+ cells (C, D) and lymphoid CD19+ cells (E, F) into the human popula-
tion at 3 (A, C, E) and 6 (B, D, F) weeks after transplantation. Results are expressed as medians (range). IV, intravenous injection; IB, 
intrabone injection in right femur; CD34, human CD34+ cells; MSC, mesenchymal stem cells.
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by flow cytometry. Mice receiving only IV CD34 were 
used as controls.
Human engraftment was expressed as percentage 
of human CD45+ cells present among the total number 
of BM or PB MNCs (Fig. 1). Regarding the injected 
femur (right), 3 weeks after transplantation (Fig. 1A), 
higher human hematopoietic cells were observed in all 
new combinations when compared with CD34+ cells IV 
injection. The highest percentage of human chimerism 
was observed in mice receiving IV infusion of both cell 
types (MSCs and CD34+ cells). Regarding left femurs 
only mice receiving IV, CD34+ cells together with MSCs 
showed a higher human hematopoietic chimerism than 
other groups, independent of the injection route of MSCs 
(Fig. 1B).
Six weeks after transplantation (Fig. 1C, D), the high-
est BM human engraftment was observed in mice which 
had received MSCs and CD34+ cells by IB injection 
(Fig. 1C). In the left femur, no differences were observed 
at week 6 (Fig. 1D).
When percentage of human CD45+ cells was analyzed 
in PB (Fig. 2), no differences among the different study 
groups and time points were observed (Fig. 2A, B).
In order to analyze the engraftment of myeloid cells, 
monocytes, B- and T-cells, CD13+, CD14+, CD19+, and 
CD3+ cell subsets were determined, respectively, within 
the human CD45+ cell population.
At week 3, when PB was evaluated, only the group 
receiving both cell types intravenously showed higher level 
of human myeloid cells (Fig. 2C). Also, CD19+ cells were 
only detected in MSC-receiving groups (Fig. 2E). Six weeks 
after transplantation, in PB, the groups with HSCs IV and 
MSCs showed higher level of lymphoid cells (Fig. 2F).
At 3 weeks, in BM, the majority of human cells showed 
CD13 expression with similar number of positive cells in 
all groups (Fig. 3A, B). CD19+ cells were mainly detected 
in MSC-receiving groups (Fig. 3C, D) producing higher 
differences with no MSC groups.
In the latest period, in BM, the percentage of myeloid 
cells among human population was decreased, while the 
Figure 3. Human hematopoietic subpopulations in NOD/SCID bone marrow at week 3. Percentage of hematopoietic subpopulation of 
human myeloid cells (CD13+) (A, B) and lymphoid cells (CD19+) (C, D) within the total human population in bone marrow from both 
femurs right (A, C) (injected site) and left (contralateral) (B, D) at week 3 after transplantation. Results expressed as medians (range). 
IV, intravenous injection; IB, intrabone injection in right femur; CD34, human CD34+ cells; MSC, mesenchymal stem cells.
MSC AND INTRABONE DELIVERY FOR UCB TRANSPLANTATION 1177
CD19+ population was increased (Fig. 4). In all groups, the 
percentage of CD19+ cells in both femurs was more than 
30% with the highest level in the left femur of mice receiv-
ing both MSCs and HSCs by IV injection (Fig. 4D).
Monitoring of Luciferase-Transduced MSCs in Mice
Human-transduced MSCs were injected IV or IB in 
mice at the time of hematopoietic transplantation. The day 
after IV injection of MSCs, cells were mainly detected in 
lungs (Fig. 5). In some cases, a focal spot of biolumines-
cence was observed at the injection site. After IB injec-
tion, cells were detected at two levels: lungs and right 
femurs (injection site). No differences were observed 
regarding the hematopoietic transplantation route; both 
groups receiving IB MSC injection with IV or IB CD34 
cells had a similar distribution of MSCs.
In all cases, signal from lungs decreased and was not 
detectable 2 weeks after injection. By contrast, signal 
from injected femurs could be detected during the whole 
study period (Fig. 5).
For luciferase signal quantification, defined ROIs were 
used over the lung and right femur.
The mean peak BLI signal intensities of 1 day after trans-
plantation was 3.1 ´  109, 5.9 ´  109, and 4.6 ´  109 photons per 
second in IV CD34+ IB MSCs, IV CD34+ IV MSCs, and 
IB CD34+ IB MSCs, respectively. After 14 days, BLI signal 
intensities decreased in lungs to background signal intensity 
(Fig. 6A). However, BLI signal intensities of groups with 
IB MSC injection was maintained from day +1 to day +42: 
4.8 ´  1010 to 4.9 ´  109 and 4.6 ´  1010 to 3.1 ´  109 in photons 
per second in IV CD34+ IB MSCs and IB CD34+ IB MSCs, 
respectively (Fig. 6B).
Detection of Human Cells Within Murine BM
Six weeks after transplantation, mice were killed, and 
femurs were fixed for immunofluorescence detection 
of human cells. Human mitochondria staining allowed 
detecting human cells and GFP expression and the dif-
ferentiation between human MSCs (GFP+) and human 
hematopoietic cells (GFP−).
Human hematopoietic cells in BM were mainly dis-
tributed in femur epiphysis showing higher numbers 
close to the injected site (epiphysis near to the knee) in 
groups receiving IB injection (Fig. 7A–C). These cells 
Figure 4. Human hematopoietic subpopulations in NOD/SCID bone marrow at week 6. Percentage of hematopoietic subpopulation of 
human myeloid cells (CD13+) (A, B) and lymphoid cells (CD19+) (C, D) within the total human population in bone marrow from both 
femurs, right (A, C) (injected site) and left (contralateral) (B, D), at week 6 after transplantation. Results expressed as medians (range). 
IV, intravenous injection; IB, intrabone injection in right femur; CD34, human CD34+ cells; MSC, mesenchymal stem cells.
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formed colonies of round-shaped cells and were grow-
ing together close to subendosteal region (Fig. 7D–F). 
Usually, cases with higher chimerism showed a similar 
trend of human cells by immunohistochemistry.
Human MSCs were only detected in femurs where 
they were previously injected and were mainly located 
in femur epiphysis (Fig. 7A–C), but few GFP-positive 
cells could be detected in each femur. These cells showed 
fibroblastic or polygonal shape and could be detected 
at two levels: some of them were distributed between 
hematopoietic cells or close to the endosteum, but oth-
ers showed a clear perivascular distribution (Fig. 7G–I). 
Blood vessels surrounded by human MSC-derived cells 
were located in a subendosteal region but not associated 
with human hematopoietic cells.
DISCUSSION
Although both strategies have been shown to be use-
ful separately (6,35,40,55), in the current manuscript, we 
have assessed together the role of intrabone administra-
tion of HSC and MSC coadministration in the cord blood 
xenotransplantation model. To study their homing abil-
ity and functional dynamics, MSCs were administered 
via intrafemoral and were transduced with a luciferase-
 expressing vector and thus tracked by bioluminescence.
UCB has emerged as an alternative source of HSCs for 
transplantation, and several studies have been focused for 
strategies to enhance UCB engraftment in adult patients 
(16,42). A higher cryopreserved MNC dose has been asso-
ciated with faster and higher probability of neutrophil 
recovery and a higher CD34+ cell dose with better disease-
free survival (19). Since the low number of cells is critical, 
other strategies that could be used include IB transplanta-
tion of UCB cells in order to prevent cell losses (3,13). 
In a previously reported paper, Massollo et al. (34) dem-
onstrated, using a rat model, that after IB injection, most 
HSCs escaped to circulating blood as soon as 30 min after 
their administration, but their first entry contact with the 
recipient BM deeply modifies the kinetic and migratory 
characteristics of donor HSCs increasing their capability 
to cross the filter of the pulmonary capillary network and 
improves their homing in BM sites remote from the injec-
tion. Our results comparing IV and IB UCB transplantation 
showed that after IB transplantation, human hematopoietic 
cell engraftment is not only higher in the injection site 
but also demonstrates their capability to migrate far from 
Figure 5. In vivo bioluminescence imaging of NOD/SCID mice. In transplantation groups receiving human MSCs (which expressed 
luciferase), a weekly imaging of MSC distribution has been done. A representative animal is shown. The reflected light gray scale 
picture is overlaid by a pseudocolor bioluminescence image (BLI), which allows for allocating the BLI signal to the respective areas 
shown in the underlying reflected light picture.
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injection sites. This is in accordance with the previous data 
that suggest that IB injection permits engraftment even 
without previous irradiation (3).
An alternative to enhance HSC engraftment is to improve 
BM microenvironment function. The influence of BM 
stroma in hematopoiesis and the axis stromal-derived factor 
1/chemokine (C-X-C motif), receptor 4 (SDF1/CXCR4) 
is a key regulator of both homing and lodgment of HSCs 
in the niche (38). In this line, improving BM stroma by 
the coadministration of MSCs is an attractive approach. 
Several studies have been designed to test this possibility 
by using MSCs from different sources (21,30,37). In this 
regard, using placental MSCs in a murine model, Hiwase 
et al. showed that MSC coinfusion could increase both 
single and double unit UCB transplantation (21). In the 
present study, the effect of MSC coinfusion in both trans-
plantation settings, IV or IB injection of HSCs, was tested. 
We could show in accordance with previous data that when 
IV transplantation was performed, the addition of MSCs 
increased human chimerism. When MSC injection route 
was analyzed, the human engraftment was higher even in 
femurs not receiving MSCs, demonstrating the capability 
of MSCs to migrate or to act far from the injection site. 
The effect of MSCs was higher in the injected femur, and it 
was more evident 6 weeks after transplantation. Although 
it was not the aim of the current study, taken into account 
our results, it would be of interest to perform the xeno-
transplant experiments with limiting doses of hematopoi-
etic stem cells and also with different doses of MSCs. This 
should be considered in the future to reinforce the results 
and to assess the effects of the cell dose in this setting.
It would be also of interest to assess in future works 
if the same strategy (intrabone administration with or 
without MSCs) also enhances engraftment of human PB 
or BM hematopoietic stem cells, although in PB or BM 
HSCT the cell dose is not as relevant as in the cord blood 
transplantation setting. Nevertheless, it could be useful in 
the autologous transplantation, especially in those cases 
of multitreated patients or poor mobilizers.
The next aim of the present work was to know how 
MSCs exert their effect. Data relating to their engrafting 
capability in recipient tissues are controversial (1,27,53). 
In the current study, we tracked the human MSCs until 
6 weeks after transplantation by using BLI. The use of BLI 
for detection of spatial distribution of transplanted MSCs 
was validated by detecting emitted photons. Sequential 
evaluation of grafted cell viability was possible with the 
BLI system since the luciferin–luciferase reaction depends 
on ATP, and only living cells release photons (23). The first 
studies tried to find MSC in BM recipients after HSCT 
(27,43,53). Due to the low number of MSCs present in 
BM samples, only in cases of patients with osteogenesis 
imperfecta (27) or a disease with high stromal damage 
some MSCs from donor origin could be detected (53). It 
has been reported that, when MSCs have been IV injected, 
most of them were retained in lungs microvasculature, and 
they could not be detected in BM (54). These data are in 
accordance with our results. By bioluminescence, when 
cells were IV injected, they were only detected during 
2 weeks after transplantation. Using a more sensitive tech-
nique as immunohistochemistry, 6 weeks after transplanta-
tion, human MSCs could not be detected either.
To improve MSC local effects, new trials searching for 
new routes of administration are being explored (49,51). 
Local injection of MSCs as intracoronary (57), intrautero 
(27), kidney (7), or skin injection (48) showed higher 
engraftment. Taking in account the results in IB injection 
of hematopoietic cells (22,44), we have considered that this 
route of delivery could be optimal for MSC administration. 
In fact, some groups are testing the use of this cells by IB 
injection in cases of bone damage as multiple myeloma (28). 
We have shown that, when MSCs were locally injected (in 
BM), they could engraft in recipient BM, and they could be 
followed for at least 6 weeks. 
Their spatial distribution within the BM was also stud-
ied. For years, the main niche for HSCs in BM has been 
the osteoblastic niche (2,39). Due to their osteoblastic dif-
ferentiation capability, endosteal region has been assumed 
Figure 6. Quantitative analysis of BLI production. The in vivo 
presence of human MSCs was measured by bioluminescence 
photometry. In mice lungs, photon flux was going down, and it 
was not detectable after week 2 (A). By contrast, in previously 
injected femurs, the signal was reduced during the first 4 weeks, 
but then its photon emission was maintained (B).
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as an optimal niche for MSCs (39). We were able to detect 
human MSCs near the BM endosteum. But recent stud-
ies have described another vascular niche, located in BM 
sinusoids, where HSCs could also be found (14). Some 
groups have described an MSC population located around 
these blood vessels (2,29). After the immunofluorescence 
analysis, we could also find human MSCs, GFP-positive, 
around blood vessels close to the subendosteal region. This 
fact is also in accordance with recent data suggesting that 
endothelial cells might form part of the subendosteal niche 
and together constitute a common niche where both endos-
teum and sinusoids contribute to hematopoiesis (2).
In summary, our results show that in our model MSCs 
could increase hematopoietic engraftment in both IB and IV 
hematopoietic transplantation. Nevertheless, they were only 
found in BM recipients after IB injection of MSCs showing 
a subendosteal and perivascular location within the BM.
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